IrsiCaixa

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

ICREA research professor at the IrsiCaixa AIDS Research Institute

Head of the Virology and Cellular Immunology group at the IrsiCaixa AIDS Research Institute

Head of the Infectious Diseases Service at the Germans Trias i Pujol Hospital and senior researcher at the AIDS Research Institute (IrsiCaixa).

Contents related to this centre
VIH

Stem cell transplants in cancer patients have achieved complete remission of HIV in a few cases in people who are also HIV-positive. However, in most cases, the donors were homozygous—with two identical copies of the gene—for a mutation in the CCR5 gene that is considered protective against the virus. A German team has now reported a new case of remission in a 60-year-old man with leukemia—called the “second Berlin patient”—in which the donor was heterozygous (only one of the two copies contained the mutation), which could broaden the alternatives. The results are published in the journal Nature.

 

breastfeeding

The risk of HIV transmission through breastfeeding is very low, but it is not non-existent in women living with HIV who have undetectable levels in their blood. Now, for the first time, a study published in the Annals of Internal Medicine has been able to test for HIV in the milk of two such women: one elite controller (who maintains low viral loads without antiretrovirals) and another who had been on treatment for years. Although small amounts of viral DNA were found, the virus was not infectious. The results show that such testing is possible and help confirm the very low risk of transmission.

HIV

The Science group is simultaneously publishing four papers (two in the journal Science, one in Science Immunology and one in Science Translational Medicine) that include advances in a sequential vaccination strategy for an effective HIV vaccine. The methods employed aim to obtain broad-spectrum neutralising antibodies and one of the proposals is already in clinical trials. 

fármacos

A study published in the New England Journal of Medicine has analysed the effectiveness of the antiviral drug Paxlovid after implantation of the omicron variant. The relative risk of severe disease decreased markedly in patients over 65 years of age, both vaccinated and unvaccinated. No differences were found in those under 65 years of age.